Mon panier

Monoclonal Anti-Hendra virus F glycoprotein Antibody, Human IgG1 (1A7) (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
FUN-MY2097-100ug
$415.00
FUN-MY2097-1mg (500ug X 2)
$2735.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Source

    Monoclonal Anti-Hendra virus F glycoprotein Antibody, Human IgG1 (1A7) is a recombinant chimeric monoclonal antibody expressed in HEK293, which combines the variable region of a mouse monoclonal antibody with human constant domain.

  • Antibody Type

    Recombinant Monoclonal

  • Clone

    1A7

  • Isotype

    Human IgG1, Kappa

  • Host Species

    Mouse

  • Reactivity

    Hendra virus

  • Immunogen

    Recombinan Hendra virus Pre-Fusion glycoprotein (A263T) is expressed from human HEK293 cells

  • Specificity

    Specifically recognizes Hendra virus Pre-Fusion glycoprotein (A263T).

  • Application

    Application
    Recommended Usage
    Western Blot
    10-5 ug/mL
    ELISA
    0.2-2 μg/mL
  • Purification

    Protein A purified / Protein G purified.

  • Aggregation

    Less than 10%, as determined by SEC-MALS.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Lyophilized

  • Formulation

    Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Reconstitution

    Please refer to the Certificate of Analysis (CoA) for specific instructions.

  • Shipping

    Lyophilized product is shipped at ambient temperature.

  • Storage

    For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Bioactivity-ELISA

     Fusion glycoprotein ELISA

    Immobilized Hendra virus Pre-Fusion glycoprotein (A263T), His Tag (Cat. No. FUN-H52H4) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Hendra virus F glycoprotein Antibody, Human IgG1 (1A7) (Cat. No. FUN-MY2097) with a linear range of 0.6-9.8 ng/mL (QC tested).

    Protocol
  • Western Blot

     Fusion glycoprotein WESTERN BLOT
  • Detection of Monoclonal Anti-Hendra virus F glycoprotein Antibody, Human IgG1 (1A7), Human IgG1 | Human Kappa, HEK by Western Blot. Monoclonal Anti-Hendra virus F glycoprotein Antibody, Human IgG1 (1A7), Human IgG1 | Human Kappa, HEK at 5ug/ml dilution + Hendra virus Pre-Fusion glycoprotein (A263T), His Tag at 400ng.
    Secondary Antibody: (HFC)-HRP Goat Anti-Human IgG,Fcγ fragment specific (min X Bov,Hrs,Ms Sr Prot) at 1/2000 dilution.
    Predicted band size: 65 kDa 12% Bis-Tris Protein Gel.

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Respiratory syncytial virus F protein

  • Catégorie:

  • Nombre de médicaments répertoriés:

    3 Détails

  • Nombre de médicaments cliniques:

    7 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte